历史大底来了？2000亿医疗巨头，董事长总经理等集体出手大买，外资机构调研超400次

Core Viewpoint - The recent stock purchases by the executives of Mindray Medical, including Chairman Li Xiting, indicate strong confidence in the company's future growth and intrinsic value, especially as the company anticipates a recovery in domestic business and continued international expansion [1][4][11]. Group 1: Executive Stock Purchases - Chairman Li Xiting has invested approximately 29.99 million yuan by purchasing 152,300 shares at an average price of 196.862 yuan per share, marking his first stock buy [3][4]. - Li Xiting plans to continue purchasing shares in the secondary market, with a total investment expected to reach 200 million yuan over the next six months [4]. - Other executives, including General Manager Wu Hao and Senior Vice President Li Zaiwen, have also made significant stock purchases, indicating a collective confidence in the company's prospects [6][7]. Group 2: Foreign Institutional Interest - Mindray Medical has attracted significant attention from foreign institutional investors, ranking second in the number of investigations among A-share listed companies, with 404 inquiries as of December 3 [1][8]. - The interest from foreign institutions reflects their strong belief in Mindray's potential, especially as the company has shown signs of recovery in its financial performance [8]. Group 3: Financial Performance and Market Outlook - In the third quarter of 2025, Mindray Medical reported a revenue increase of 1.53% year-on-year, reversing a previous decline of 23.77% in the second quarter [1][8]. - The company expects domestic business to recover to positive growth in 2026, with profit growth anticipated to turn positive as well [11]. - Mindray's international market potential is estimated to be 4-5 times larger than the domestic market, positioning the company for long-term growth in international business [11][13]. Group 4: Strategic Focus - Mindray is focusing on expanding its market share in the domestic market, particularly in the IVD (in vitro diagnostics) sector, which is expected to drive future growth [11]. - The company aims to leverage its "equipment + IT + AI" strategy to address the increasing demand for efficiency and cost control in global healthcare [13]. - Mindray's international business has shown robust growth, with a 11.9% increase in the third quarter, particularly strong in Europe and developing countries [13].